Dr. Anke Krebs

Partner, dompatent

 

Experience

Dr. Anke Krebs is a Partner and German Patent Attorney at dompatent in Cologne, specializing in high-profile pharmaceutical patent disputes. She has represented clients in major cases at the Düsseldorf Regional Court, including the Novartis fingolimod battle against eight generics companies and Biogen's Tecfidera proceedings against generic manufacturers such as Glenmark and Hexal. Her work involves preliminary injunctions and opposition proceedings at the European Patent Office.

Specialty

Dr. Anke Krebs specializes in pharmaceutical law and chemistry-related intellectual property, providing comprehensive advice on patent prosecution, enforcement, and litigation. She is part of Dompatent's Chemistry/Pharmaceuticals expertise team and contributes to the firm's China Desk for international IP matters.

Education

Dr. Anke Krebs holds a degree as Graduate Chemist, a Doctor of Natural Science in Chemistry, and an LL.M. in European Industrial and Intellectual Property Rights. She is qualified as a German Patent Attorney and European Patent Attorney.

Achievements and Recognition

• Listed as IP expert in Pharmaceutical and biotechnology / Chemistry in JUVE Patent 2025 Germany rankings for patent filing (https://www.juve-patent.com/firm-rankings/rankings-germany-2025/patent-filing-germany-2025/).
• Named as speaker at the 10th IP Forefront Pharma Forum (IFPF 2025) (http://pharmaip.cn/english/).
• Co-author of article on patenting computer-implemented simulation at the EPO (2022) (https://www.dompatent.de/en/patenting-computer-implemented-simulation-at-the-epo/).
• Co-author of article on success attracting imitators in IP context (2022) (https://www.dompatent.de/en/those-who-succeed-attract-imitators/).